CD38 and neoplasm: CD38/CD47 BsAbs preferentially bound to CD38+/CD47+ Reh cells, indicating that compared to CD47 therapeutic Abs, BsAbs have lower potential for on-target, off-tumor effects in vivo (Figure 7).